Can a chelation treatment ease symptoms of gadolinium buildup?
NCT ID NCT06269055
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study from Stanford University looked at whether a chelation treatment using Ca-DTPA and Zn-DTPA can help people with gadolinium deposition disease, a condition where gadolinium from MRI contrast dye builds up in the body. Researchers interviewed 30 adults who had received at least five treatment sessions to see if their symptoms improved and what side effects occurred. The goal was to understand the potential benefits and risks of this approach.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethylenetriamine pentaacetate (Zn-DTPA)
- What this could lead to
- If successful, this could point toward a treatment that eases symptoms of gadolinium deposition disease.
- What could go wrong
- This is a small, completed study with only 30 participants, so results may not apply to everyone. Side effects from chelation therapy are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients in the U.S. who developed Gadolinium Deposition Disease (GDD) within 28 days of undergoing a contrast-assisted MRI, in which the contrast agent contained the metal gadolinium, and who retained enough gadolinium to have abnormally high 24-hour urine levels 28 or more days post MRI. Participants must satisfy the Inclusion/Exclusion criteria noted above.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 or older, 2. Diagnosis of Gadolinium Deposition Disease (GDD) established by treating MD according to current criteria and confirmed by investigator review of screening questionnaire (dx criteria: presence of at least 3 of 8 symptoms-cognitive disturbance, extremity pain, arthralgia, chest wall pain, skin pain, headache, skin induration, and skin hyperpigmentation; and, had an unprovoked 24-hour Gd urine excretion level exceeding the laboratory norm at least 28 days after the symptom-inducing MRI; 3. has had five or more 2-day chelation treatments with Ca-DTPA/Zn-DTPA; 4. will be at least 2 weeks post the last chelation treatment at the time of completing the patient data-gathering questionnaires. 5. no more than 2 years have elapsed since the last DTPA chelation. Exclusion Criteria: 1\. Not fluent in written and spoken English; 2. having impaired hearing that significantly decreases the person's ability to communicate via telephone; 3. Prisoners; 4. Unable to provide informed consent; 5. Participating or having participated in protocols involving a pharmacological treatment of GDD other than DTPA chelation. Note: brief pre- or post-DTPA chelation to prevent GDD symptom flare is not an exclusion criterion. \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ca-dtpa are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University Medical Center
Stanford, California, 94305, United States